I think that this is a really important point and shouldn't be over-looked by anyone invested in RAC.If CPACS is proven (the big 'if' for RAC), it is important to be aware that this wouldn't just offer the potential to just protect the heart when receiving anthracyclines (and other cancer drugs), it potentially offers to improve cancer outcomes and also protecting the heart. CPACS = Cardio Protective Anti Cancer Synergy.
The potential benefit for cancer patients from CPACS is big. It can be the difference between receiving anthracyclines if you are in a high heart risk group and not being able to receive them. It could be the difference between being given a higher dose of chemo instead of a lesser dose. It can potentially be the difference between being able to receive a further round of chemo after relapse or reoccurrence. The impact of survivability would be truly immense... if CPACS is proven we are talking about life and death.
The value for a CPACS drug is up to everyone to work out for themselves, so too is the chances that RAC has a FIC/BIC CPACS drug which is supported by a strong commerical strategy that will be executed.
RAC Price at posting:
$1.79 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)